Compare WEYS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | ALDX |
|---|---|---|
| Founded | 1906 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 336.3M |
| IPO Year | N/A | 2014 |
| Metric | WEYS | ALDX |
|---|---|---|
| Price | $30.06 | $5.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 20.8K | ★ 722.4K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $279,843,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $63.48 |
| P/E Ratio | $11.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.51 | $1.14 |
| 52 Week High | $38.24 | $7.20 |
| Indicator | WEYS | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 58.41 |
| Support Level | $28.69 | $4.70 |
| Resistance Level | $30.73 | $5.35 |
| Average True Range (ATR) | 1.35 | 0.29 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 37.48 | 78.17 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.